Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Nelson

Interventional Pain Medicine Kirkland, WA Medical Doctor

NPI 1205878469 CMS profile 145701

12911 120Th Ave Ne, Suite H-210, Kirkland, WA 98034

Open in the dashboard

General payments

$29,314

319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Nelson of Kirkland, WA is reported in the CMS Open Payments database as having received $29,314 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,516 40
2024 General $3,028 40
2023 General $1,748 37
2022 General $2,230 36
2021 General $2,603 43
2020 General $7,245 52
2019 General $8,944 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Nelson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Daniel Nelson were reported at $3,516. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Daniel Nelson Interventional Pain Medicine median Middle half National median
2019 $8,944 $684 $216–$2,079 $163
2020 $7,245 $382 $122–$1,109 $114
2021 $2,603 $552 $167–$1,554 $132
2022 $2,230 $605 $187–$1,924 $149
2023 $1,748 $671 $195–$1,915 $160
2024 $3,028 $684 $206–$1,837 $164
2025 $3,516 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $14,561 196 payments
  2. SI-BONE, Inc. $5,704 4 payments
  3. Nalu Medical, Inc. $1,809 15 payments
  4. MML US, Inc. $1,621 6 payments
  5. Vertiflex, Inc. $1,425 15 payments
  6. Relievant Medsystems, Inc. $912 5 payments
  7. Nevro Corp. $827 16 payments
  8. BIOTRONIK NRO, Inc. $452 7 payments
  9. Biotronik Inc. $448 2 payments
  10. Painteq LLC $264 4 payments
  11. Other $1,291 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,548 297 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,000 2 payments
  3. Consulting Fee $5,600 1 payment
  4. Travel and Lodging $5,166 19 payments
Products named General payments · program years 2019–2025
  1. SUPERION $6,197 8 payments
  2. IFUSE IMPLANT $5,600 1 payment
  3. Nalu Neurostimulation System $1,809 15 payments
  4. ReActiv8 $1,621 6 payments
  5. WaveWriter Alpha Prime 16 $1,525 30 payments
  6. Superion ISS $1,425 15 payments
  7. GENERAL PAIN MANAGEMENT $1,390 49 payments
  8. Intracept Intracept Drill_NMOD $1,047 5 payments
  9. General - Pain Management $937 25 payments
  10. Intracept Pain $912 5 payments
  11. Other $6,209 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$221,290

Of which drugs: $534

Medicare patients

311

Average age 75

Services billed

2,829

178 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 62%
Ischemic heart disease 22%
Osteoporosis 20%
Depression 17%
Atrial fibrillation 16%
Chronic kidney disease 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 74 264 $202
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 164 1,272 $113
Injection, midazolam hydrochloride, per 1 mg J2250 Office 48 171 $19

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record